Episode Details

In our latest Trade To Black podcast presented by Flowhub, host Shadd Dales sits down with Avicanna (TSX:AVCN / OTCQX:AVCNF) CEO Aras Azadian and Dr. Karolina Urban, Executive Vice President of Scientific and Medical Affairs, to talk about what U.S. cannabis rescheduling could mean for cannabinoid-based medicine.With the DOJ and DEA now moving certain cannabinoid products into a Schedule III framework, the big question becomes simple:Which companies are actually ready for a more pharmaceutical, evidence-based model?Avicanna (TSX:AVCN / OTCQX:AVCNF) has spent years building around clinical research, real-world evidence, standardized formulations, intellectual property, and medical cannabis care models. In this interview, Aras and Dr. Urban explain why that matters now, especially as U.S. regulators begin looking more seriously at FDA pathways, clinical trials, dosing, safety, reproducibility, and physician-guided treatment.The conversation also covers Avicanna’s chronic pain research, its rapid-onset delivery platform, MyMedi.ca, pharmacist-led support, international medical cannabis opportunities, and the company’s upcoming clinical symposium in Toronto.This isn’t just about cannabis moving to Schedule III.It’s about what comes next—and which companies are actually built for the medical and pharmaceutical side of the industry.#Avicanna #AVCN #CannabisNews #MedicalCannabis #CannabisRescheduling #CannabinoidMedicine #Biotech #TradeToBlack #Flowhub #CannabisInvestingWant to see more Cannabis Reform?🎬    • Congress Tries To Slow Cannabis Reform | T...  🎬    • DEA Moves On HHC — What It Means | TDR Can...  🎬    • DOJ Signals Shift On Cannabis & Firearms |...  🎬    • Cannabis + Psychedelics: What Just Changed...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:

Listen Now